8-K: Harmony Biosciences Reports Strong Q2 2024 Results, Advances Pitolisant Pipeline

Harmony Biosciences announced a 29% year-over-year increase in net revenue for Q2 2024, driven by strong sales of WAKIX and progress in its pitolisant high-dose program.

Summary

• Harmony Biosciences reported a 29% increase in net product revenue for the second quarter of 2024, reaching $172.8 million compared to $134.2 million in the same period of 2023.
• The growth was primarily driven by strong commercial sales of WAKIX, which is used to treat narcolepsy.
• The average number of patients on WAKIX increased by approximately 250 sequentially to approximately 6,550 for the quarter ended June 30, 2024.
• GAAP net income for the quarter was $11.6 million, or $0.20 earnings per diluted share, compared to $34.3 million, or $0.56 earnings per diluted share, for the same period in 2023.
• The decrease in GAAP net income was primarily due to a $25.5 million upfront licensing fee and a $17.1 million IPR&D charge.
• Non-GAAP adjusted net income was $60.6 million, or $1.05 earnings per diluted share, compared to $45.9 million, or $0.76 per diluted share, for the same period in 2023.
• Research and Development expenses increased significantly to $63.6 million, primarily due to the licensing fee and IPR&D charge.
• The company reiterated its 2024 net product revenue guidance of $700 to $720 million.
• Harmony Biosciences is advancing its pitolisant high-dose program with an expected PDUFA date in 2028, aiming to extend the pitolisant franchise beyond 2040.
• The company received FDA approval for WAKIX for the treatment of EDS in pediatric patients with narcolepsy and launched it on July 1, 2024.
• A supplemental new drug application for pitolisant in Idiopathic Hypersomnia is on track for submission in the fourth quarter of 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, successful patent defense, and pipeline advancements. The decrease in GAAP net income is offset by the increase in non-GAAP adjusted net income and the company's strong cash position. The company is executing well on its strategy and has a clear path for future growth.

Positives

• Strong revenue growth of 29% year-over-year for WAKIX in Q2 2024.
• Increase in the number of patients using WAKIX, indicating strong market demand.
• Successful defense of the WAKIX patent against challenges.
• FDA approval and launch of WAKIX for pediatric narcolepsy.
• Advancement of the pitolisant high-dose program with promising PK data.
• Progress in the pipeline with multiple clinical trials and regulatory submissions planned.
• Reiteration of the 2024 net product revenue guidance of $700 to $720 million.
• The company has a strong cash position with $434.1 million in cash, cash equivalents and investments.

Negatives

• GAAP net income decreased significantly compared to the same period in 2023, primarily due to a $25.5 million upfront licensing fee and a $17.1 million IPR&D charge.
• Research and Development expenses increased substantially due to the licensing fee and IPR&D charge.
• Total operating expenses increased by 92% compared to the same quarter in 2023.

Risks

• The company's future results are subject to risks and uncertainties, including the success of clinical trials and regulatory approvals.
• There is significant competition in the pharmaceutical industry.
• The company's intellectual property position is crucial for its success.
• The company's share price may be volatile and fluctuate substantially.
• The company is subject to government laws and regulations.

Future Outlook

The company expects full year 2024 net product revenue of $700 million to $720 million and anticipates at least one new product or indication launch every year over the next five years, with multi-billion-dollar revenue potential extending beyond 2040.

Management Comments

• We made substantial progress and continue to advance our pitolisant high-dose development program, targeting a PDUFA date in 2028, giving us the opportunity to extend the pitolisant franchise beyond 2040, said Jeffrey M. Dayno, M.D., President and Chief Executive Officer of Harmony.
• We also delivered another strong quarter of revenue growth for WAKIX, confirming our confidence in WAKIX being a billion dollar plus market opportunity in narcolepsy alone, while gaining the approval and launching WAKIX in pediatric narcolepsy.

Industry Context

The announcement highlights Harmony Biosciences' continued growth in the narcolepsy market with WAKIX, while also expanding its pipeline with new treatments for other rare neurological diseases. The company's focus on developing differentiated products and extending patent protection positions it well for long-term growth in the competitive pharmaceutical landscape.

Comparison to Industry Standards

• Harmony's 29% year-over-year revenue growth for WAKIX is strong compared to the average growth rates of other pharmaceutical companies in the rare disease space.
• The company's focus on lifecycle management of pitolisant with the development of GR and HD formulations is a common strategy to extend the commercial life of a drug, similar to how companies like AbbVie have managed Humira.
• The expansion into pediatric narcolepsy with WAKIX is a strategic move to capture a larger patient population, similar to how companies like Jazz Pharmaceuticals have expanded the use of Xyrem.
• The development of TPM-1116, an orexin-2 receptor agonist, puts Harmony in competition with companies like Idorsia, which are also developing orexin-based therapies for sleep disorders.
• The company's pipeline includes treatments for Fragile X syndrome, Dravet syndrome, and Lennox-Gastaut syndrome, which are areas of high unmet need, similar to the focus of companies like Ultragenyx and BioMarin.

Stakeholder Impact

• Shareholders will benefit from the strong revenue growth and pipeline advancements.
• Employees will be impacted by the company's growth and expansion.
• Patients will benefit from the development of new treatments for rare neurological diseases.
• Customers will have access to new and improved treatment options.
• Suppliers will benefit from the company's increased demand for products and services.
• Creditors will be impacted by the company's financial performance and debt management.

Next Steps

• Submit a supplemental new drug application for pitolisant in Idiopathic Hypersomnia in the fourth quarter of 2024.
• Initiate a Dosing Optimization study for Pitolisant Gastro-Resistant in the fourth quarter of 2024.
• Initiate a Pivotal Bioequivalence study for Pitolisant Gastro-Resistant in the first quarter of 2025.
• File an IND for TPM-1116 in mid-2025.
• Initiate first-in-human studies for TPM-1116 in the second half of 2025.
• Obtain topline data from the Phase 3 RECONNECT registrational trial of ZYN002 in Fragile X syndrome in mid-2025.
• Initiate a Phase 3 trial for EPX-100 in Lennox-Gastaut syndrome later this year.
• Host an investor day in New York City on October 1st.

Key Dates

Keywords

WAKIX, pitolisant, narcolepsy, idiopathic hypersomnia, sleep disorders, pharmaceutical, revenue, clinical trials, FDA approval, patent, CNS, rare diseases